文献速递前列腺癌前列腺增生与排尿功能障碍

机器人辅助根治性前列腺切除术后泌尿症状变化与生活质量:一项随机对照试验的二次分析

Urinary Symptoms Change and Quality of Life After Robotic Radical Prostatectomy: A Secondary Analysis of a Randomized Controlled Trial.
PubMed 文献 · Urology · 2024-01-26

该研究为前瞻性随机对照试验的二次分析,纳入213例机器人辅助根治性前列腺切除术后尿失禁的局限性疾病男性,随机接受盆底肌训练、度洛西汀、联合治疗及居家盆底肌锻炼。结果显示中重度泌尿症状从术前48%降至术后3、6、12个月的40%、34%、23%,仅大前列腺与临床重要差异改善相关,神经血管束保留与术后舒适度及更高中位IIEF-5相关。

要点

  • 中重度泌尿症状从术前48%降至术后12个月的23%。
  • 术后临床重要差异改善见于19%患者,恶化见于3.3%。
  • 大前列腺是临床重要差异改善的唯一相关因素(OR 1.03)。

核心结论

  • 尽管机器人辅助根治性前列腺切除术后存在尿失禁,前列腺较大的患者在一年内下尿路症状减轻,进而提升生活质量。
  • 保留神经的手术增强勃起功能与泌尿结局,塑造术后生活质量。

研究设计与样本

  • 前瞻性随机对照试验的二次分析,纳入213例局限性疾病且机器人辅助根治性前列腺切除术后尿失禁的男性。
  • 患者随机接受盆底肌训练、度洛西汀、盆底肌训练联合度洛西汀及居家盆底肌锻炼。

主要发现

  • 中重度泌尿症状从术前48%降至术后3、6、12个月的40%、34%、23%。
  • 术后临床重要差异改善见于19%患者,恶化见于3.3%。
  • 大前列腺是临床重要差异改善的唯一相关因素(OR 1.03 [95%CI 1.01-1.05],P = .005)。
  • 术后6个月患者达到与术前相同程度的满意度。
  • 神经血管束保留是术后泌尿症状舒适度的唯一预测因素(术后3个月 OR 12.8 [95%CI 1.47-111.7],P = .02),并与更高的术后中位IIEF-5相关。

关键数值与推荐

  • 临床重要差异改善定义为国际前列腺症状评分差值ΔIPSS ≤ -8分。
  • 泌尿症状负担定义为IPSS ≥8分。
  • 患者满意定义为IPSS生活质量评分≤2分,舒适定义为视觉模拟量表≤1分。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present the patient-reported quality of life (QoL) outcomes from a prospective, randomized controlled trial comparing the use of pelvic floor muscle training (PFMT) and duloxetine after robot-assisted radical prostatectomy (RARP). METHODS: We identified 213 men with organ-confined disease having post-RARP urinary incontinence who were randomly assigned to received PFMT, duloxetine, combined PFMT-duloxetine and pelvic floor muscle home exercises. Urinary symptoms burden was measured by marked clinical important difference improvement (MCID) defined by using the International Prostate Symptom Score (IPSS) difference of - 8 points (ΔIPSS ≤-8). QoL was assessed according to Visual Analog Scale (VAS), King's Health Questionnaire (KQH), and International Index of Erectile Function (IIEF-5). Multivariable regression analyses aimed to predict MCID, burden of urinary symptoms (IPSS ≥8), and patients reporting to be satisfied (IPSS QoL ≤2) or comfortable (VAS ≤1) post-RARP. RESULTS: Moderate to severe urinary symptoms decreased from 48% preoperatively to 40%, 34%, and 23% at 3, 6, and 12months post-RARP. After surgery, MCID improvement was observed in 19% of patients, and deterioration in 3.3%. Large prostate was the only factor associated to MCID (OR 1.03 [95%CI 1.01-1.05], P = .005). At 6months, patients reached the same degree of preoperative satisfaction. Neurovascular bundle preservation was the only predictor of being comfortable regarding urinary symptoms postoperatively (OR 12.8 [CI95% 1.47-111.7], P = .02 at 3months) and was also associated to higher median postoperative IIEF-5. CONCLUSION: Despite urinary incontinence following RARP, patients with larger prostates experience a reduction of lower urinary tract symptoms within a year, which subsequently elevates QoL. Furthermore, nerve-sparing surgery augments erectile function and urinary outcomes, shaping postoperative QoL.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Tourinho-Barbosa R, Sanchez-Salas R, Sivaraman A, et al. Urinary Symptoms Change and Quality of Life After Robotic Radical Prostatectomy: A Secondary Analysis of a Randomized Controlled Trial. Urology. 2024. PMID: 38281669. doi:10.1016/j.urology.2023.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。